• CNS, Psychiatry & Neurology
  • Allergy & Immunology
  • Pain
  • Addiction & Substance Use Disorder
  • Respiratory
  • Obesity & Cardiometabolic
Dr. Vince Clinical Research
  • About
    • Company Brochure
    • Leadership Team
    • Vision
    • Envisioned Around Technology
    • Green Certification
    • Careers
    • Photo Gallery
  • Services
    • Clinical Pharmacology Unit
    • Specialized Studies
    • Multi-Site Model
    • Support Services
    • Clinical Laboratory
    • Tobacco Harm Reduction
    • Recruitment and Retention
  • Therapeutic Areas
    • Overview
    • CNS, Psychiatry & Neurology
    • Allergy & Immunology
    • Pain
    • Addiction & Substance Use Disorder
    • Respiratory
    • Obesity & Cardiometabolic
  • Resources
    • Blogs
    • Brochure
    • Fact Sheets
    • Publications
    • Videos
    • Webinars
    • White Papers
  • News
  • Volunteer Website
  • Request Information
Select Page
10 Lessons Learned Over 40 Years of Drug Development Research in Psychiatry

10 Lessons Learned Over 40 Years of Drug Development Research in Psychiatry

Publications

Sheldon Preskorn, MD, Senior Vice President of Neuroscience, presented “10 Lessons Learned Over 40 Years of Drug Development Research in Psychiatry” at the 2024 CNS Summit. Dr. Preskorn provided strategies for enhancing clinical trial design, minimizing patient...
Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration

Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration

Publications

Lynn Webster, MD, Executive Vice President of Scientific Affairs, recently presented his poster titled “A Review of the Primary and Secondary Outcomes From a Phase I Study Comparing the Respiratory Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride...
Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access

Publications

Our Executive Vice President of Scientific Affairs, Dr. Lynn Webster, has released a co-authored review on opioid abuse-deterrent formulations (ADFs). This comprehensive analysis delves into the effectiveness of ADFs in reducing misuse and abuse while highlighting the...

Recent Posts

  • Full-Service CRO Overview.
  • Early QT/TQT Studies
  • Definitive QT Evaluation – Clinical and Operational Considerations
  • FDA’s New Draft Guidance on Non-Opioid Analgesics: A Needed Shift in Chronic Pain Treatment
  • Dr. Vince Clinical Research Announces First Dosing in Atopic Dermatitis Patients with Enveda’s First-in-Class Investigational Drug ENV-294

Recent Comments

    Contact Us

    (913) 333-3000

    Headquarters

    7401 W. 91st Street
    Overland Park, KS
    66212 USA

    ABOUT

    • Company Brochure
    • Leadership Team
    • Vision
    • Envisioned Around Technology
    • Green Certification
    • Photo Gallery

    SERVICES

    • Clinical Pharmacology Unit
    • Specialized Studies
    • Multi-Site Model
    • Support Services
    • Clinical Laboratory
    • Tobacco Harm Reduction
    • Recruitment and Retention

    THERAPEUTIC AREAS

    • CNS, Psychiatry & Neurology
    • Allergy & Immunology
    • Pain
    • Addiction & Substance Use Disorder
    • Respiratory
    • Obesity & Cardiometabolic

    RESOURCES

    NEWS

    Dr. Vince Clinical Research Logo

    Connect with us!

    • Follow
    • Follow
    Contact Us Today

    Privacy Policy | Terms & Conditions